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Abstract 
Background: Limited data suggest that personal lubricants may damage the vaginal mucosal epithelium, alter the 
vaginal microbiota, and increase inflammation. We compared vaginal cytokine profiles and microbiota before and 
after vaginal lubricant use and condomless vaginal sex.
Methods: Reproductive-age women were recruited to a 10-week observational cohort study and were asked to 
self-collect vaginal samples and behavioral diaries daily. This nested case–control analysis utilized samples collected 
before and after self-reported condomless sexual activity with lubricants (22 case participants) and without lubricants 
(22 control participants). Controls were matched to cases on race/ethnicity. Microbiota composition was character-
ized by sequencing amplicons of the 16S rRNA gene V3–V4 regions. Cytokine concentrations were quantified using 
a magnetic bead 41-plex panel assay and read using a Bio-Plex 200 array reader. Wilcoxon signed-rank tests were 
used to assess baseline differences in vaginal cytokines between cases and controls as well as differences pre- and 
post-exposure. Linear mixed effects models were used to examine differences in relative post-to-pre change in each 
individual cytokine between matched cases and controls. Similar analyses were conducted for the microbiota data.
Results: Mean age was 29.8 years (SD 6.8), and 63.6% were African American. There were few statistically significant 
changes in cytokines or microbiota before and after exposure in cases or controls. In mixed-effects modeling, the 
mean relative post-to-pre change of cytokines was higher in cases vs. controls for macrophage derived chemokine 
(MDC) (p = 0.03). The microbiota data revealed no significant changes when measured by similarity scores, diversity 
indexes and descriptive community state types (CST) transition analyses. However, post sexual activity, the mean 
relative abundance of L. crispatus decreased for those who used lubricants (particularly those who were L. iners-domi-
nated prior to exposure).
Conclusions: Although there were overall few differences in the vaginal microbiota and cytokine profiles of lubricant 
users and controls before and after condomless vaginal sex, there was a trend toward decreases in relative abundance 
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Background
Over 60% of American women report use of personal 
lubricants during intimate sexual activities [1]. Vaginal 
lubricants are also often administered to improve com-
fort during clinical gynecological exams. As most of these 
products are classified by the Food and Drug Adminis-
tration (FDA) as cosmetics, human safety data is not 
required prior to commercialization. The FDA classifies 
lubricants for clinical use as class II medical devices, a 
category that may pose moderate risk to high to patients 
[2]. Prior work has linked vaginal products containing 
nonoxynol-9 (a spermicide) to increased inflammation 
and risk of HIV acquisition in women [3]. Of concern, 
non-spermicide containing lubricants have been linked 
to enhanced vaginal susceptibility to sexually transmitted 
infections (STIs) in animal models [4] and to an increased 
risk of rectal STIs in men who have sex with men [5].
The mechanisms for this enhanced risk with non-sper-
micide containing lubricants are unclear, but may relate 
to mucosal epithelial damage and increased inflamma-
tion as well as to changes in local bacterial populations, 
because lubricants are often formulated with anti-micro-
bial preservatives such as chlorhexidine [6, 7]. Stud-
ies have suggested that some lubricants may inhibit the 
growth of Lactobacillus species, an essential component 
of an optimal vaginal microbiota, thus promoting vagi-
nal dysbiosis [6, 8–11]. This may be important as lack 
of vaginal lactobacilli, in particular lack of Lactobacillus 
crispatus dominance, has been shown to be associated 
with significant increase in susceptibility to STIs [12] 
and HIV acquisition [13]. Additionally, many lubricants 
are formulated with high concentrations of substances 
such as glycerol or propylene glycol [14]. These concen-
trated humectants make them feel comfortably warm 
when applied to the skin, but also make them markedly 
hypertonic to mucosal epithelia [6, 14]. Many commer-
cially available lubricants have osmolalities above the 
World Health Organization (WHO) recommended limit 
of 1200 mOsm/kg [15, 16]. Multiple studies have shown 
that hypertonic lubricants may be toxic to mucosal epi-
thelial cells, inducing significant epithelial cell shedding 
in in-vitro and animal models as well as in humans [6, 7, 
17, 18]. For example, one study showed that application 
of a lubricant with an elevated osmolality caused shed-
ding of large sheets of epithelial cells from rectal tissue 
[7]. An in vitro study using a three dimensional model of 
the human vaginal epithelium demonstrated that high 
osmolality lubricants markedly reduced epithelial barrier 
properties and induced damage to tissue structures [19].
Elevations in levels of specific “pro-inflammatory” vagi-
nal cytokines have been associated with BV, STIs and 
enhanced acquisition of HIV [13, 20–22]. Several studies 
have investigated the impact of vaginal microbicide gels 
or candidate carrier lubricants on cytokines in the human 
vagina or upper reproductive tract as potential markers 
of inflammation, irritation and therefore enhanced HIV 
acquisition [23–25]. However, none have examined the 
impact of routine use of vaginal lubricants in women 
who had condomless vaginal intercourse as compared to 
condomless vaginal intercourse without lubricant use on 
both vaginal cytokines and microbiota in a methodical 
fashion. Despite widespread use, the impact of commer-
cially available vaginal lubricants on the vaginal microen-
vironment, inflammation and immunity is understudied. 
Based on our current knowledge, we hypothesized that 
we would observe a larger increase in (1) pro-inflamma-
tory vaginal cytokines and chemokines and (2) strict and 
facultative anaerobic bacteria in women reporting use of 
personal vaginal lubricants (purchased over the coun-
ter) during condomless vaginal sex (cases) as compared 
with women engaging in condomless vaginal sex with-
out lubricant use (controls). In order to test this hypoth-
esis, herein, we compared women’s vaginal cytokine and 
microbiota profiles before and after condomless vaginal 
sex with or without vaginal lubricant use.
Methods
This is a nested case–control study utilizing existing 
samples from a parent longitudinal study conducted 
between 2009 and 2010 at the University of Alabama at 
Birmingham (UAB)  [26]. For the parent observational 
cohort study, HIV-negative, reproductive-age, non-preg-
nant, cis-gender women were recruited and followed 
over 10 weeks. All women underwent a pelvic examina-
tion and microscopy prior to enrollment to evaluate for 
symptomatic bacterial vaginosis, vaginal candidiasis, or 
trichomoniasis. Additionally, an endocervical swab was 
sent for nucleic acid amplification testing for gonorrhea 
and chlamydia. If a diagnosis of a STI or symptomatic 
condition was made at baseline, patients were offered 
treatment but excluded from the study. Participants were 
offered the opportunity to return to attempt enrollment 
again 30  days after treatment was completed. Each day, 
participants self-collected mid-vaginal swabs and filled 
of L. crispatus following use of lubricant. Future larger studies that take into account osmolarity and composition of 
lubricants may provide additional insights.
Keywords: Vaginal lubricants, Immunology, Bacterial vaginosis, Sexually transmitted infections
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out behavioral diaries (yes/no fields). Dry swabs used 
for cytokine analyses were placed in empty tubes, and 
swabs used for microbiota analyses were placed in tubes 
containing Amies transport medium. All swabs were 
promptly frozen in participants’ home freezers before 
being returned to the research clinic in weekly batches on 
frozen ice packs. Once returned, tubes were transferred 
to long-term storage in −80°C freezers. Samples for 
cytokine quantification underwent a total of two freeze 
thaw cycles (one for aliquoting and a final thaw for analy-
sis). All methods were carried out in accordance with rel-
evant guidelines and regulations.
For this analysis, we first selected vaginal samples col-
lected before and after self-reported lubricant use with 
condomless vaginal intercourse (cases). For compari-
son, we then chose vaginal samples from race-matched 
women collected before and after self-reported condom-
less vaginal intercourse without report of lubricant use 
(controls) (Fig. 1A, B). For the majority of participants, an 
individual exposure day (i.e., one day with reported lubri-
cant use or condomless vaginal sex) was identified, and 
samples collected on the days immediately before and 
after this exposure were selected (after confirming these 
days were exposure-free). For participants with consecu-
tive exposure days, the next appropriate day after expo-
sure ended was selected.
Cytokine characterization
Prior to analysis, frozen, dry vaginal swabs were eluted 
into 1  mL of PBS. The eluates were then aliquoted and 
stored at −80°C until immediately before analysis. 
Cytokine concentrations in undiluted eluates were quan-
tified in duplicate using a magnetic bead 41-plex panel 
assay (Millipore HCYTMAG60PMX41BK) performed 
according to the manufacturer’s recommended protocol 
and read using a Bio-Plex 200 array reader (Bio-Rad). 
Data were analyzed using Bio-Plex manager software 
(Bio-Rad). All samples were assayed in a single batch and 
manufacturer-provided internal controls were included 
on each assay plate. The 41 measured cytokines and 
chemokines included: interferon alpha (INF-α), inter-
feron gamma (INF-γ), interleukin 1 alpha (IL-1α), inter-
leukin 1 beta (IL-1β), interleukin 1 receptor antagonist 
(IL-1RA), interleukin 2 (IL-2), interleukin 3 (IL-3), inter-
leukin 4 (IL-4), interleukin 5 (IL-5), interleukin 6 (IL-6), 
interleukin 7 (IL-7), interleukin 8 (IL-8), interleukin 9 
(IL-9), interleukin 10 (IL-10), interleukin 12 heterodimer 
p40 and p35 (IL-12p70), interleukin 12 homodimer p40 
(IL-12p40), interleukin 13 (IL-13), interleukin 15 (IL-
15), interleukin 17 alpha (IL-17α), tumor necrosis factor 
alpha (TNF-α), epidermal growth factor (EGF), fibroblast 
growth factor (FGF), granulocyte colony stimulating fac-
tor (GCSF), granulocyte–macrophage colony-stimulating 
factor (GM-CSF), monocyte chemotactic protein 1 
(MCP-1), interferon gamma-induced protein 10 (IP-10), 
macrophage Inflammatory protein 1 alpha (MIP-1α), 
macrophage inflammatory protein 1 beta (MIP-1β), 
tumor necrosis factor beta (TNF-β), vascular endothelial 
growth factor (VEGF), FMS-like tyrosine kinase 3 ligand 
(Flt-3L), fractalkine, growth related protein (GRO), 
monocyte chemotactic protein-3 (MCP-3), macrophage 
derived chemokine (MDC), platelet derived growth fac-
tor AA dimer (PDGFa), platelet derived growth factor AB 
and BBdimer (PDGFab), soluble CD40 ligand (sCD40L), 
RANTES (CCL5), eotaxin, and transforming growth fac-
tor alpha (TGF-α).
Vaginal microbiota characterization
Vaginal swabs that had been stored in Amies liquid 
transport medium at −80°C were selected, thawed, and 
prepared for genomic DNA extraction. The validated 
procedures employed have been previously published 
[26]. In brief, enzymatic and physical lysis of bacterial 
cells was followed by purification of genomic DNA using 
a QIAsymphony robotic platform and QIAGEN Cell-
Free 500 kits (QIAGEN, Valencia, CA, USA) according 
to the manufacturer’s protocol. This procedure provided 
between 2.5 and 5 μg of high-quality genomic DNA from 
300  μl of each sample swab stored in Amies transport. 
The V3–V4 hypervariable regions of the 16S rRNA genes 
were targeted from genomic DNA using bacterial prim-
ers 338F and 806R and were amplified by a two-step 
polymerase chain reaction (PCR) method [27]. Amplicon 
pooling, sequencing on an Illumina HiSeq 2500 instru-
ment using a modified PE300 protocol, sequence data 
pre-processing, and taxonomic assignments were con-
ducted as described by Holm et al. [28]. Vaginal micro-
biota were assigned community state types (CSTs) [29] 
using VALENCIA (https:// github. com/ ravel- lab/ VALEN 
CIA), a nearest-centroid-based algorithm [30]. Four CSTs 
indicated dominance by Lactobacillus—L. crispatus (CST 
I), L. gasseri (CST II), L. iners (CST III), or L. jensenii 
(CST V). CST IV, a low-Lactobacillus state, was divided 
based on the presence and relative abundance of anaero-
bic organisms—BVAB1 and Gardnerella vaginalis (CST 
IV-A), G. vaginalis and Atopobium vaginae (CST IV-B), 
Prevotella spp. and others (CST IV-C) [30, 31].
Statistical analyses
In order to compare baseline behavioral characteristics 
between matched cases and controls, asymptotic sym-
metry and marginal homogeneity tests were used for 
categorical variables, McNemar’s chi-square tests for 
binary variables, and paired t-tests or Wilcoxon signed-
rank tests for continuous variables. For samples with 
vaginal cytokine measurements below the lower limit 
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of detection, a number halfway between 0 and the low-
est measured value for that particular cytokine for that 
particular plate was imputed [32]. Cytokines that were 
below the level of quantitation in > 90% of all samples (IL-
2, IL-3, IL-5, IL-9, IL-10, IL-15, TNF-β) were excluded 
from the analysis. One analyte, IL-1RA, was above 
Fig. 1 A Longitudinal plot for controls (n = 22) including instances of self-reported condomless vaginal sex without lubricant use and pre- and 
post-exposure samples selected for analysis. B Longitudinal plot for cases (n = 22) including instances of self-reported condomless vaginal sex with 
lubricant use and pre- and post-exposure samples selected for analysis
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the upper limit of quantitation in 96% of samples and 
excluded from the analysis. In seven samples one ana-
lyte other than IL-1RA was above the upper limit. These 
seven values were imputed as 10,000  pg/mL, the upper 
limit of quantitation for the assay. Wilcoxon signed-rank 
tests were used to assess baseline differences in vaginal 
cytokine levels between matched cases and controls and 
differences in cytokines between pre- and post-exposure 
samples. We assessed differences in pre-exposure sam-
ple CSTs between cases and controls with the marginal 
homogeneity test. The Shannon Diversity Index (SDI) 
was calculated to measure the diversity of bacterial spe-
cies within each vaginal sample [33]. The pre-exposure 
sample SDI was subtracted from the post-exposure value; 
a positive change in SDI indicated greater bacterial spe-
cies diversity in the post-exposure sample. We then com-
pared the median SDI change values between cases and 
controls using the Wilcoxon signed-rank test. In addi-
tion, we assessed the Yue Clayton theta distance [34], 
which measured the similarity in bacterial communities 
between pre- and post-exposure samples, and compared 
the theta distances for cases and controls using the Wil-
coxon signed-rank test.
Linear mixed-effects and generalized linear mixed-
effects models were used to assess differences in indi-
vidual cytokines before and after exposure, and by 
case–control status. In the linear mixed-effects mod-
els for the cytokine analysis, the outcome was the 
 log10-transformed ratio of the post-exposure cytokine 
level and the pre-exposure cytokine level (i.e., the rela-
tive post-to-pre change), and a normally distributed ran-
dom effect term was used to adjust for matched pairs. 
For the vaginal microbiota analysis, to assess post-to-pre 
differences in the relative abundance of specific bacte-
rial taxa, we employed similar modeling methods. Linear 
mixed-effects models were used to assess differences in 
the most abundant bacterial taxa before and after expo-
sure by case–control status. To calculate the post-to-pre 
relative abundance ratio outcome for each bacterial taxa, 
we added a constant (1) to the relative abundances in all 
samples and divided the post-exposure relative abun-
dance value by the pre-exposure value to obtain a ratio 
(Formula 1), which was then  log10-transformed. A nor-
mally distributed random effect term was included in the 
model to adjust for matched pairs.
Formula 1:
Principal component analysis (PCA) was  also con-
ducted to visualize the pre- to post-exposure cytokine 
ratio in cases versus controls. Following an approach 
Ratio =
("Post" sample relative abundance)+ 1
("Pre" sample relative abundance)+ 1
presented by Arnold et al. [35], we defined a binary meas-
urement for “inflammation” as having at least three out 
of seven predetermined inflammatory cytokines (IL-1α, 
IL-1β, IL-8, MIP-1α, MIP-1β, IP-10, and RANTES) in the 
upper quartile. MIP-1α and IP-10 were added to the list 
of inflammatory cytokines based on relevant data from 
Masson et al. [36] showing a strong association with HIV 
seroconversion. A logistic mixed-effects model adjust-
ing for matched pairs and within-subject correlations 
between pre- and post-exposure measures was applied 
with the binary inflammation score as the outcome. All 
analyses were conducted using STATA v14 (Stata Corp, 
College Station, TX) and R. PCA plots were constructed 
utilizing SIMCA 15 (Umetrics AB, Umea, Sweden).
Results
Paired pre- and post-exposure samples from 22 lubri-
cant users and 22 race-matched controls were analyzed 
for a total of 88 samples. 63.6% of participants were 
African American, and the mean age was 30  years (SD 
6.8) (Table 1). There were no statistically significant dif-
ferences between cases and controls in terms of age, 
douching, hormonal contraception (HC) use, or num-
ber of sexual partners, though cases were more likely to 
report lubricant use in the prior 6 months as compared 
to controls (p = 0.03) (Table 1, also see Additional file 2: 
Table  S5 for data). Although cases reported more con-
domless vaginal sex compared to cases (average report-
ing of 3  days versus 7  days, respectively), the difference 
was not statistically significant (p = 0.25; Fig. 1A, B).
Cytokine analysis
Prior to exposure, the median eotaxin, Flt-3L, and PDG-
Fab were significantly higher in cases as compared to 
controls (Additional file 1: Table S1) with a similar trend 
in VEGF. Among controls, Wilcoxon signed-rank tests 
indicated that when comparing cytokines pre- to post-
exposure as continuous measures, the median MCP-3 
and sCD40L levels were significantly higher before expo-
sure (Additional file 1: Table S2), with a similar trend in 
IL1-7α. There were no significant differences when com-
paring median cytokines post- to pre-exposure within 
cases (lubricant users), though there was a trend towards 
higher median eotaxin pre-exposure (p = 0.05) (Addi-
tional file 1: Table S3).
In mixed-effects modeling, adjusting for log-trans-
formed baseline cytokine level, the mean log-trans-
formed relative pre- to post-exposure change of cytokines 
was higher in cases as compared to controls for MDC 
(p = 0.03), (Additional file 1: Table S4). A PCA plot of the 
pre- to post-exposure cytokine ratios (Fig. 2) showed no 
clear grouping using the first two principal components 
by case–control status. Sample 8 had a higher value in the 
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first principal component, while sample 21 had a higher 
value in the second principal component. These differ-
ences do not appear to be driven by any single cytokine.
Using a logistic mixed-effects model to analyze the 
binary inflammation score, there were no statistically sig-
nificant differences in the odds of having an inflammatory 
vaginal microenvironment between cases and controls 
adjusting for whether it was sampled prior to or following 
exposure, within-subject correlations, and matched pairs 
(p = 0.16). Furthermore, there were no significant dif-
ferences in the odds of having an inflammatory vaginal 
microenvironment between cases and controls in the 
pre-exposure samples after adjusting for matched pairs 
(p = 0.16). Finally, there were no significant differences 
in the odds of having an inflammatory vaginal microen-
vironment between pre- and post-exposure measures 
Table 1 Demographic and behavioral characteristics
HC: hormonal contraception, CST: community state type. Cases were more likely to report vaginal lubricant use in the last 60 days (p = 0.03). There were no statistically 
significant differences between cases and controls in terms of age, race, douching, hormonal contraception (HC) use, number of sexual partners or pre-exposure pH, 






users n = 22
Age, Mean (SD) 29.8 (6.8) 30.5 (7.0) 29.1 (6.8)
Race
 African American 28 (63.6) 14 (63.6) 14 (63.6)
 White 14 (31.8) 7 (31.8) 7 (31.8)
 Latina 2 (4.6) 1 (4.6) 1 (4.6)
Douching frequency last 60 days
 None 32 (72.7) 15 (68.2) 17 (77.3)
 Monthly 3 (6.8) 3 (13.6) 0 (0.0)
 Every now and then 3 (6.8) 1 (4.6) 2 (9.1)
 No answer 6 (13.6) 3 (13.6) 3 (13.6)
Vaginal Lubricant use last 60 days (Y)* 11 (25.6) 2 (9.1) 9 (42.9)
Current HC use (Y) 11 (25.0) 5 (22.7) 6 (27.3)
Number sex partners last 60 days
 0 3 (6.8) 2 (9.1) 1 (4.6)
 1 37 (84.1) 19 (86.4) 18 (81.8)
 2 4 (9.1) 1 (4.6) 3 (13.6)
Pre-exposure sample pH*
 4.0–4.5 25 (58.1) 12 (54.6) 13 (61.9)
 4.6–5.0 10 (23.3) 6 (27.3) 4 (19.1)
 > 5.0 8 (18.6) 4 (18.2) 4 (19.1)
Pre-exposure sample Nugent category
 No BV 23 (52.3) 13 (59.1) 10 (45.5)
 Intermediate 8 (18.2) 2 (9.1) 6 (27.7)
 BV 13 (29.6) 7 (31.8) 6 (27.7)
Pre-exposure sample CST**
 CST-I, L. crispatus-dominated 8 (18.2) 6 (28.6) 2 (9.1)
 CST-II, L. gasseri-dominated 5 (11.4) 2 (9.5) 3 (13.6)
 CST-III, L. iners-dominated 14 (31.8) 5 (23.8) 9 (40.9)
 CST-IVA, Low Lactobacillus 7 (15.9) 3 (14.3) 4 (18.2)
 CST-IVB, Low Lactobacillus 6 (13.6) 3 (14.3) 3 (13.6)
 CST-IVC, Low Lactobacillus 2  (4.5) 1 (4.8) 1 (4.5)
 CST-V, L. jensenii-dominated 1 (2.3) 1 (4.8) 0 (0.0)
Pre-exposure sample CST**
 CST-I/II/V, L. crispatus/gasseri/jensenii-dominated 14 (32.6) 9 (42.9) 5 (22.7)
 CST-III, L. iners-dominated 14 (32.6) 5 (23.8) 9 (40.9)
 CST-IVA/B/C, Low Lactobacillus 15 (34.9) 7 (33.3) 8 (36.4)
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within controls (p = 0.14) or cases (p > 0.99) after adjust-
ing for within-subject correlations. Due to the small 
sample size and exploratory intent of the pilot study, cor-
rection for multiple comparisons was not conducted, but 
none of our findings would have been significant after 
correction according to the Bonferroni method.
Vaginal microbiota analysis
The distribution of pre-exposure CSTs between cases 
and controls was similar whether a 7-CST (p = 0.56) or a 
3-CST scheme (p = 0.29) were used, with the proportion 
of participants having a low-Lactobacillus sample prior 
to exposure being nearly equal in both groups (Table 1). 
The CSTs and bacterial taxa relative abundances of the 
samples included in the analysis are shown in Fig.  3. 
There were 3 (13%) CST-discordant case pairs (pre- and 
post-exposure samples) and 5 (24%) CST-discordant con-
trol pairs. The pre-to-post CST transitions observed were 
Lactobacillus-dominated to CST IV-B or CST IV-C  (2 
cases), CST IV-B to CST III (2 controls), CST IV-A to 
CST IV-B (1 case and 2 controls), and CST V to CST III 
(1 control).
The median change in SDI was -0.03 and 0.02 for cases 
and controls, respectively (Additional file 1: Figure S1A). 
These results suggest slightly higher species diversity 
in pre-exposure samples for cases and post-exposure 
Fig. 2 Principal components analysis of pre- to post-exposure cytokine ratios. Blue circles indicate cases (lubricant users) and green circles indicate 
controls
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samples for controls; however, the differences by case–
control status were not statistically significant (p = 0.24). 
The median Yue Clayton theta distance was 0.72 for cases 
and 0.65 for controls  indicating both had relatively high 
similarity, and there were no statistically significant dif-
ferences in post-to-pre bacterial taxa between cases and 
controls (p = 0.52, Additional file 1: Figure S1B).
When focusing on the seven taxa with the highest rela-
tive abundance, there were no statistically significant 
differences between pre-exposure samples comparing 
cases and controls. The adjusted linear mixed-effects 
models showed a significant difference in the mean 
 log10-transformed post-to-pre relative abundance 
between cases and controls only for L. crispatus 
(p = 0.014) (Table 2). When controlling for the pre-expo-
sure sample L. crispatus relative abundance, the mean 
post-to-pre L. crispatus relative abundance ratio was 
lower (i.e., mean post-exposure relative abundance was 
lower than the pre-exposure relative abundance, produc-
ing a ratio < 1) in cases compared to controls. This find-
ing is demonstrated in the relative abundance bar charts 
(Fig.  3). Among cases whose pre-exposure sample was 
classified as L. iners-dominated CST III, but also had a 
sizeable proportion of L. crispatus present, L. crispatus 
abundance was significantly lower after lubricant expo-
sure in the post-exposure sample. There were no exam-
ples of controls with pre-exposure samples that were 
CST III with high L. crispatus relative abundance, and 
Fig. 3 Bacterial relative abundances
Table 2 Top 7 most abundant taxa in the vaginal microbiota comparing mean post-to-pre-exposure ratio by case or control status
SD  standard deviation, BVAB1  bacterial vaginosis associated bacteria 1
Taxa Controls
Mean post/pre ratio (SD)
Cases
Mean post/pre ratio (SD)
Generalized mixed 
effect model p-value
L. iners 1.03 (0.19) 1.01 (0.12) 0.91
L. crispatus 1.00 (0.01) 0.96 (0.10) 0.01
Gardnerella vaginalis 1.00 (0.09) 1.02 (0.06) 0.10
L. jensenii 1.00 (0.02) 1.00 (0.03) 0.97
L. gasseri 1.03 (0.12) 1.01 (0.12) 0.46
Atopobium vaginae 0.99 (0.03) 1.00 (0.05) 0.40
Candidatus Lachnocurva vaginae (formerly BVAB1) 0.98 (0.06) 0.99 (0.04) 0.12
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the same trend was not seen in cases or controls with 
pre-exposure samples that were classified as L. crispatus-
dominated CST I.
Discussion
Despite our hypothesis that we would observe a larger 
increase in pro-inflammatory cytokines and chemokines 
after lubricant use in this observational cohort, there 
were few statistically significant differences in vaginal 
cytokine profiles before and after exposure in lubricant 
users versus controls. For the three cytokines (Flt-3L, 
PDGFab, and eotaxin) which were statistically signifi-
cantly different between the two groups at baseline, there 
was no statistically significant pre- to post-exposure 
change between groups in multivariate modeling. The 
post- to pre-exposure change of only one chemokine 
(MDC) was statistically significantly different between 
groups in multivariate modeling. MDC is a chemokine 
that recognizes the CCR4 receptor, is selective for Th2 
cells, and expression has been shown to be induced by 
IL-4 and IL-13 [37–39]. MDC is one of seven cytokines 
that was found in a LASSO cytokine model to classify 
women as STI/BV positive or negative [21]. However, 
the lack of differences in MDC comparing pre- and post-
exposure samples in lubricant users and the lack of dif-
ferential change in other inflammatory cytokines or 
chemokines in lubricant users versus controls makes it 
difficult to interpret this isolated result. Certainly, in this 
cohort, there is no clear pattern to suggest a markedly 
pro-inflammatory vaginal microenvironment induced 
by lubricant use. Some previous studies (primarily from 
in vitro models) had raised concerns regarding the abil-
ity of lubricants (especially hyperosmolar lubricants) 
to lead to mucosal irritation and epithelial cell damage 
[6, 7, 9, 17, 40]. If true, this presumably would lead to a 
pro-inflammatory vaginal cytokine profile with potential 
implications for women’s reproductive health, including 
elevated risk of acquisition of STIs and HIV. While a sin-
gle study found transcriptional upregulation of inflam-
matory genes in the upper reproductive tract with the use 
of a “universal placebo gel” previously thought to be inert 
[25], the results of our study are supported by results 
from two other placebo-controlled microbicide studies in 
which neither placebo vaginal lubricant nor microbicide 
resulted in increases in cervicovaginal pro-inflammatory 
cytokines [23, 24].
Other than direct cellular toxicity, concerns have been 
raised that lubricants could negatively impact the vagi-
nal microbiota, leading to decreases in beneficial lacto-
bacilli [9, 41], which in turn might have implications for 
reproductive health including increased susceptibility 
to STIs and HIV [31, 42]. We similarly hypothesized 
there would be a larger increase in strict and facultative 
anaerobic bacteria post-exposure in lubricant users 
compared to controls. We did not detect such a dif-
ference. Overall, we found few statistically significant 
differences at baseline between lubricant users or con-
trols or changes in the overall structure of the vaginal 
microbiota before and after lubricant use. However, 
one taxon, L. crispatus, had higher relative abundance 
in pre-lubricant samples compared to post-exposure 
samples for cases. This is interesting given other stud-
ies have found a lack of L. crispatus dominance to be 
associated with a significant increase in susceptibility 
to HIV acquisition [13]. This is also noteworthy in light 
of several recent in  vitro studies. The first found that 
the feminine moisturizer Vagisil inhibited L. crispatus 
growth [9]. Another found that two lubricant prod-
ucts (Replens Long-Lasting moisturizer and Trimo-
San) inhibited the growth of L. crispatus, while another 
product (Replens Silky Smooth) enhanced growth [41]. 
A third paper found that lubricants containing chlo-
rhexidine gluconate or nonoxynol-9 significantly inhib-
ited Lactobacillus spp. growth, while other lubricants 
decreased the attachment of lactobacilli to vaginal epi-
thelial cells in vitro [11]. These results, and ours, point 
to the need for larger, controlled studies to under-
stand the impact of specific lubricants on the vaginal 
microbiome.
Animal and in vitro studies have suggested that expo-
sure to semen may elicit the expression of pro-inflam-
matory cytokines in the vaginal tract [43, 44]. One study 
by Sharkey et  al. demonstrated upregulation of several 
cytokine mRNAs in the human cervix, including IL-1α, 
IL-6, and IL-8, 12 h after condomless vaginal intercourse 
compared to 36  h prior [45]. We did not observe these 
changes in our analysis of pre- and post-vaginal sex expo-
sures. In fact, of the cytokines or chemokines that were 
statistically significantly different in pre- and post-expo-
sure samples (MCP-3 and sCD40L), all were lower post-
vaginal sex than pre-vaginal sex. There could be several 
reasons for this. First, the area sampled and the analyses 
were different: the Sharkey study utilized cervical biop-
sies and looked for mRNA expression; we utilized vaginal 
swabs and directly measured secreted cytokine concen-
trations. Secondly, there was more variability in the tim-
ing of when our “post” sample was taken in relation to 
sexual intercourse (generally 12–36  h after). Further-
more, in the Sharkey study, patients used condoms for 
5 days and then completely abstained from sexual inter-
course for 2  days before the study was conducted. Our 
samples were taken from an observational cohort, and we 
did not require women to abstain from intercourse. It is 
possible that differences pre- and post-exposure to semen 
might be blunted in women engaging in regular sexual 
intercourse.
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A strength of our study is the race-matched pre- to 
post-exposure design that enabled us to systematically 
assess real-world vaginal lubricant use in women com-
pared to vaginal intercourse without lubricant, allowing 
us to assess if any findings were the result of lubricant 
use versus inflammatory changes following sexual activ-
ity/vaginal intercourse. We matched on race as it was 
strongly associated with lubricant use and CST in the 
Parent study, and based on prior literature, has been 
associated with several unmeasured factors (e.g., sexual 
networks and health behaviors) that may confound this 
analysis [46, 47]. We were unable to match on pre-expo-
sure CST due to low sample size. However, future studies 
may investigate how various vaginal bacterial communi-
ties are affected by lubricant exposure, as CSTs may have 
varying resilience to extrinsic exposures.
Our research group [48, 49] and others [50–53] have 
validated self-collection of mid-vaginal swabs used for 
immunologic and microbiota analyses, and the practice 
is now widely used. The daily at-home sampling allows 
population-based longitudinal field studies. Our samples 
underwent two freeze thaw cycles. Several studies have 
shown low numbers (≤ 2) of freeze thaw cycles have neg-
ligible impact on the concentration of most cytokines 
[54–58]. Additionally, we focused on higher abundant 
bacterial taxa in this analysis. Data from gut microbiota 
literature suggests that storage of samples over hours to 
days at room temperature gives similar results to freezing 
immediately at –80°C, with only very low abundant taxa 
being affected [59–62]. Given the fact that samples were 
quickly frozen, we do not anticipate that the storage pro-
tocols would have affected the relative abundance of the 
relevant, highly abundant taxa.
However, there are significant limitations to our study. 
The daily diary did not collect information on which 
specific lubricants women used, and therefore, we were 
unable to assess whether these lubricants had elevated 
osmolalities or contained anti-microbial components. 
While there is a range of osmolalities and ingredients 
across commercially available personal lubricant prod-
ucts, in the period of time that this study was conducted, 
the osmolalities of commercially available lubricants 
were generally high [6]. Nonetheless, it is still possible 
in that women using frequent or large amounts of prod-
uct, lubricants with elevated osmolalities or lubricants 
with anti-microbial components might have a different 
immune response. Secondly, since this was an explora-
tory analysis with a small sample size, we did not cor-
rect for multiple comparisons. None of our findings 
would have been statistically significant after correction 
for multiple comparisons. Thirdly, our method of impu-
tation for undetectable cytokines, while widely used in 
the literature [32, 63], does have the potential to over or 
under-estimate true cytokine levels.
Additionally, we analyzed samples taken from an 
observational cohort study  [26] that was powered for 
different aims. Small sample size was a limitation. The 
22 cases and 22 controls represent a convenience sam-
ple from the original cohort, and we were only able to 
match one control per case on race. Furthermore, we did 
not mandate that women abstain from either condom-
less sexual intercourse or vaginal lubricant use prior to 
sample collection as it was an observational study. At 
baseline, women reported their vaginal lubricant use in 
the 60 days prior to enrollment in the study. Nine cases 
(41%) and two controls (9%) reported vaginal lubricant 
use in that period, including KY-Jelly (n = 7), Vaseline 
(n = 1), Silk (n = 1), mineral oil (n = 1), and an unspeci-
fied edible lubricant (n = 1). Although we confirmed that 
controls did not use any vaginal lubricants after enroll-
ment, we were unable to verify whether cases continued 
use of the same lubricant product on the exposure day 
of interest. Post- to pre-exposure changes in cytokines 
might be blunted in women regularly engaging in con-
domless sexual intercourse or regularly utilizing vagi-
nal lubricants. Again, because this was an observational 
study based on secondary data, the timing of sampling 
after intercourse/lubricant use was not rigidly controlled. 
While most post-exposure samples were taken between 
12 and 36 h after intercourse, in 2 participants, this was 
substantially longer. It is possible that impacts on vaginal 
cytokines or microbiota are acute and short-lived (i.e., 
occurring shortly after use and quickly resolving), which 
could still lead to increased vulnerability (e.g., to HIV 
acquisition) but would not have been captured by our 
sampling methods. In addition, the methods used in this 
study to describe the vaginal microbiota do not differen-
tiate between dead and live bacteria, and it is unknown 
how long DNA from dead bacteria can be detected in the 
vagina. It is possible that bacteria that were killed imme-
diately after exposure would still be detectable in samples 
collected one day after exposure but not two or three 
days later. However, we posit that DNA detected from 
dead bacteria would constitute a small part of the result 
and not confound the observed associations.
Two participants (#44, a case, and #30, a control) had 
pre-exposure samples that had the highest similarity 
to the centroid of CST II by the VALENCIA algorithm. 
These two samples were dominated by Klebsiella and P. 
bivia, respectively but did contain a modest proportion 
of L. gasseri and were consequently placed in the L. gas-
seri-dominated CST II by the algorithm. In a sensitivity 
analysis, we reassigned these samples to CST IV-C; how-
ever, there was still no association between pre-exposure 
CST and lubricant use using marginal homogeneity tests. 
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We also did not detect a difference in post-to-pre L. gas-
seri relative abundance between cases and controls.
Finally, we estimated the presence and relative abun-
dance of key vaginal bacterial via 16S rRNA gene ampli-
con sequencing. However, it is possible that lubricant 
could affect not only the abundance of key bacteria but 
also their functional output—for example, the produc-
tion of protective lactic acid from lactobacilli. We did not 
measure vaginal metabolites in this study. The observed 
difference in L. crispatus appears to be driven by cases 
whose pre-exposure samples were L. iners-dominated 
(CST III); however, there were no comparable instances 
among controls where a pre-exposure sample was L. 
iners-dominated but with a high relative abundance of 
L. crispatus, so it remains unknown what impact sex in 
the absence of lubricant use would have on this profile. 
Behavioral diaries were submitted weekly, and there 
may have been information bias in accurately reporting 
or recalling daily lubricant use or vaginal sex. We were 
not able to verify condomless vaginal sex or lubricant use 
with any biological measures.
Conclusions
Although overall there were few differences in the vaginal 
microbiota and cytokine profiles of lubricant users and 
controls before and after condomless vaginal sex, there 
was a trend toward decreases in relative abundance of 
L. crispatus following use of lubricant. Within the limi-
tations of the observational study design, our results are 
intriguing, but far from definitive. Larger, prospective, 
well-controlled studies with higher density sampling 
to carefully assess the impact of different types of over-
the-counter vaginal lubricants, including those with high 
osmolarity, are needed to further evaluate the effect of 
vaginal lubricants on the vaginal microenvironment and 
inflammation.
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